Anand Kulkarni
Overview
Explore the profile of Anand Kulkarni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
585
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singal A, Ng M, Kulkarni A
J Clin Exp Hepatol
. 2024 Jul;
14(6):101448.
PMID: 38946864
Hepatocellular carcinoma (HCC) is one of the few cancers with a 5-year survival that has remained below 20%; however, prognosis differs by tumor stage at diagnosis. Curative treatment options among...
2.
Premkumar M, Kulkarni A, Izzy M
Hepatology
. 2024 Jun;
80(5):E79-E80.
PMID: 38922813
No abstract available.
3.
Harit M, Mundhe N, Tamoli Sr S, Pawar V, Bhapkar V, Kolhe G, et al.
Cureus
. 2024 Apr;
16(3):e56530.
PMID: 38646244
Background and objectives SIVI is a standardized extract prepared using the aerial parts of developed to enhance the quality of sleep. The objective of the present study was to the...
4.
Kim D, Yoon Y, Kim B, Choudhury A, Kulkarni A, Park J, et al.
Hepatol Int
. 2024 Feb;
18(2):299-383.
PMID: 38416312
Liver transplantation is a highly complex and challenging field of clinical practice. Although it was originally developed in western countries, it has been further advanced in Asian countries through the...
5.
Verma N, Duseja A, Mehta M, De A, Lin H, Wong V, et al.
Aliment Pharmacol Ther
. 2024 Feb;
59(6):774-788.
PMID: 38303507
Background: The precise estimation of cases with significant fibrosis (SF) is an unmet goal in non-alcoholic fatty liver disease (NAFLD/MASLD). Aims: We evaluated the performance of machine learning (ML) and...
6.
Godbole S, Juveria S, Jagtap N, Kulkarni A, Lanka P, Sheikh S, et al.
J Clin Exp Hepatol
. 2024 Jan;
14(2):101312.
PMID: 38274507
Background And Aims: Muscle disorders in cirrhosis are associated with poor outcome and need early identification. Anthropometric measures lack sensitivity, and CT-based L3-skeletal muscle Index (L3-SMI) may miss early sarcopenia....
7.
Sharma M, Alla M, Kulkarni A, Rao P, Reddy D
J Clin Exp Hepatol
. 2023 Dec;
14(1):101203.
PMID: 38076359
The management of a patient in the peri-transplantation period is highly challenging, and it is even more difficult while the patient is on the transplantation waitlist. Keeping the patient alive...
8.
Ramaswamy A, Kulkarni A, John G, Rauthan A, Patil S, Duseja A, et al.
JCO Glob Oncol
. 2023 Nov;
9:e2300215.
PMID: 38033275
Purpose: Immune checkpoint inhibitors (ICIs) is the initial line of management in advanced hepatocellular carcinoma (HCC), but survivals in the real world are not known. Materials And Methods: A retrospective...
9.
Kulkarni A, Rakam K, Avadhanam M, V P Y, Rachakonda C, Satyavadi A, et al.
Cureus
. 2023 Nov;
15(10):e47151.
PMID: 38022175
Background: Patients with cirrhosis are susceptible to infections, especially by multidrug-resistant organisms (MDROs). There are limited data on the incidence of culture-positive infections and the validity of Sepsis 3-criteria in...
10.
Kulkarni K, Kurhade S, Chendake Y, Kulkarni A, Satpute S
Bull Environ Contam Toxicol
. 2023 Sep;
111(3):33.
PMID: 37667101
Presence of colors, organic surface finishing agents and surfactants in textile industry effluent makes it highly detrimental for surrounding environment. Hence the effluent from textile industry needs treatment for removal...